Search Result for : Pharmaceutical Industry

The Dollar Business Bureau Indian Pharma exports to the US may increase in 2017-18 despite pricing pressure and stiff competition. A report released by Care Ratings said that $50 billion worth of drugs are expected to become 'off-patent' in the current year giving hope to the Indian Pharma export market. "The pharma export volumes from India to US, however, are expected to rise. This will be backed by about $55 billion expected sales gain to generics drugs on account of branded drugs going off patent during 2017-19 which will create an opportunity for CRAMS segment. We expect growth rate for CRAMS (Contract Research and Manufacturing Services) to be higher compared to average growth rate of the industry. These factors are likely to support pharma exports from India," ...

The Dollar Business Bureau  Indian pharmaceutical company, Strides Shasun Ltd, has acquired Perrigo's active pharmaceutical ingredients (APIs) manufacturing facility, based in Ambernath city of Maharashtra for Rs.100 crore.  “The company has inked a definitive agreement to acquire the complete shareholding in Perrigo API India Pvt Ltd for Rs.100 crores,” Strides Shasun said in a press release.  The deal is likely to be completed by December 31, 2016, it said.  Commenting on the deal, Shashank Sinha, Group CEO, Strides Shasun, said, “This acquisition will bring a manufacturing facility into the company’s fold which is designed to manage multi-purpose small batch productions and speed up our time to the market.”  “This goes well with the Strides' strategy of creating a backward integrated portfolio of small volume and niche ...

The Dollar Business Bureau  Pharmaceutical exports from India could go beyond $14 billion mark in 2016, touching $20 billion by 2020 and witnessing a compounded annual growth rate (CAGR) of around 8 percent, a study conducted by ASSOCHAM and TechSci Research released on Thursday said. “However, the growth in exports of pharmaceutical products from India may drop by at least half to around 8 percent during 2015-2020, from the CAGR level of 15 percent recorded during 2010-14. The decline is due to delay in approvals from regulatory bodies in major markets of the world such as US, Russia, Africa, etc,” said the joint study conducted by ASSOCHAM and TechSci Research. The study also highlighted that consolidation of pharmaceutical ...

Source: PTI    The government has given in-principal approval to set up a national investment and manufacturing zone (NIMZ) in Telengana. It has the potential to create direct employment for 75,000 people and indirect for 1,50,000 persons, Commerce and Industry Minister Nirmala Sitharaman has said in her tweets. “In-principle approval given for NIMZ in Districts: Ranga Reddy and Mehbubnagar, Telangana. “Have the potential to create direct employment for 75,000 & indirect for 1,50,000 persons. They shall have a pharmaceutical industry focus,” she said. NIMZs are mega industrial zones with world class supporting infrastructure. The National Manufacturing Policy provides for NIMZs -- mega industrial zones with world class infrastructure. The government is offering a host of incentives like exemption from capital gains tax ...

The Dollar Business Bureau The government on Wednesday decided to defer the proposed talks between the chief negotiators on India–European Union Broad-based Investment and Trade Agreement (EU-BTIA) for the present. The decision was taken as the government is disappointed and concerned by the action of EU in imposing legally binding ban on the sale of around 700 pharma products clinically tested by GVK Biosciences, Hyderabad, an official statement said. Pharmaceutical industry is one of the flagship sectors of India which has developed its reputation through strong research and safety protocols over the years and therefore the government will examine all options in this regard. It is pertinent to mention that most of these drugs are already in EU market for many years ...

Interview by Himanshu Vatsa | The Dollar Business The Dollar Business (TDB): Apart from nuclear energy and defence sector, what are the areas that have potential to strengthen the business collaboration between India and the United States? Dr. Didar Singh (DDS): In chemical, pharmaceutical, bio-technology and bio-informatics sectors. In R&D, manufacturing and trade in advanced technologies in the fields of conventional munitions, aerospace, electronics, and material sciences. Other emerging sectors with significant market opportunities include lasers, robotics, nano-technology, specialty materials, and advanced design, engineering & construction capabilities. The infrastructure sector which includes ports, airports, roads, highways, power plants, implementation of Smart City projects etc. present an enormous potential for American companies doing business in India. Dr. Didar Singh, Secretary General, FICCI TDB: ...

The Dollar Business Bureau The bio-services sector which is currently valued at US$ 5-6 billion is set to increase to US$ 50 billion soon and we should be prepared to meet this growth. V K Subburaj, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers, made the above statement at a round-table meeting on ‘Unleashing Opportunities in Bio-Services Including Contract Research & Manufacturing’, in New Delhi, on Friday. Stating that India makes pharmaceutical products worth US$ 30 billion every year and is a leading producer of generics, the Secretary expressed hope that the bio-pharmaceuticals will take over the sector in future. Speaking at the meet, the Secretary further stated that the conducive atmosphere for growth has been missing in ...

Jayarama Emani | The Dollar Business The pharmaceutical industry appreciated the recent move by US Food and Drug Administration (USFDA) to incentivize those adopting a culture of quality in addition to its usual practice of pulling up those for manufacturing lapses. Speaking to The Dollar Business, Krishna Prasad, CEO & Director, Cito Healthcare (P) Ltd; said “I am glad the agency is taking pro-active and positive steps in encouraging compliance across the industry. In the past, we have the UK MHRA (Medicines and Healthcare Products Regulatory Agency) being appreciative of some of the GCP (Good Clinical Practice) measures adopted by a sponsor or a contract research location. USFDA too have been complementing more from the CFR (Code of Federal ...